NO20050396L - Adjuvant viral partikkel - Google Patents

Adjuvant viral partikkel

Info

Publication number
NO20050396L
NO20050396L NO20050396A NO20050396A NO20050396L NO 20050396 L NO20050396 L NO 20050396L NO 20050396 A NO20050396 A NO 20050396A NO 20050396 A NO20050396 A NO 20050396A NO 20050396 L NO20050396 L NO 20050396L
Authority
NO
Norway
Prior art keywords
vlp
protein
viral particle
virus
immunogen
Prior art date
Application number
NO20050396A
Other languages
English (en)
Inventor
Denis Leclerc
Philippe Tessier
Constantio Iii Ro Lopez-Macias
Nathalie Majeau
Original Assignee
Denis Leclerc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denis Leclerc filed Critical Denis Leclerc
Publication of NO20050396L publication Critical patent/NO20050396L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/26011—Flexiviridae
    • C12N2770/26023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det beskrives en immunogen-bærer med immunopotensierende eller adjuvantegenskaper. Mer spesielt er immunogen-bæreren en viruslignende partikkel (VLP) fra familien potexvirus og mer spesielt papayamosaikkvirus. Denne VLP som fremstilles ved rekombinante teknikker er i fusjon med et av sine egne proteiner som et protein immunogen. Den ovenfor nevnte VLP og et protein eller en proteineksfrakt fra et viralt, bakterielt eller parasittalt patogen kan benyttes som en vaksine.
NO20050396A 2002-07-05 2005-01-25 Adjuvant viral partikkel NO20050396L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39365902P 2002-07-05 2002-07-05
PCT/CA2003/000985 WO2004004761A2 (en) 2002-07-05 2003-06-30 Adjuvant viral particle

Publications (1)

Publication Number Publication Date
NO20050396L true NO20050396L (no) 2005-01-25

Family

ID=30115621

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050396A NO20050396L (no) 2002-07-05 2005-01-25 Adjuvant viral partikkel

Country Status (15)

Country Link
US (2) US7641896B2 (no)
EP (2) EP2272525A3 (no)
JP (1) JP4953570B2 (no)
KR (1) KR20050044886A (no)
CN (1) CN1665528B (no)
AU (1) AU2003281246A1 (no)
BR (1) BR0312474A (no)
CA (1) CA2434000C (no)
DK (1) DK1523329T3 (no)
ES (1) ES2431963T3 (no)
HK (1) HK1075214A1 (no)
MX (1) MXPA05000287A (no)
NO (1) NO20050396L (no)
PT (1) PT1523329E (no)
WO (1) WO2004004761A2 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003281246A1 (en) * 2002-07-05 2004-01-23 Denis Leclerc Adjuvant viral particle
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
WO2006032674A1 (en) * 2004-09-21 2006-03-30 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide
US7572451B2 (en) 2004-10-25 2009-08-11 Cytos Biotechnology Ag Gastric inhibitory polypeptide (GIP) antigen arrays and uses thereof
KR100688522B1 (ko) * 2005-01-18 2007-03-02 삼성전자주식회사 영상데이터 압축기 및 압축방법
JP2009501001A (ja) 2005-06-01 2009-01-15 ダウ グローバル テクノロジーズ インコーポレイティド 多価ウイルス様粒子の製造
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
WO2012048430A1 (en) * 2010-10-14 2012-04-19 Folia Biotech Inc. Affinity-conjugated nucleoprotein-papaya mosaic virus-like particles and uses thereof
ES2562774T3 (es) * 2006-11-15 2016-03-08 Folia Biotech Inc. Vacunas para la gripe basadas en el virus del mosaico de la papaya
JP2010508857A (ja) * 2006-11-15 2010-03-25 フォリア バイオテック インコーポレイテッド パパイヤモザイクウイルスに基づく免疫原性の親和性で複合体化された抗原系及びその使用
EP2082042A4 (en) * 2007-01-26 2010-08-18 Folia Biotech Inc VACCINE VACCINE FROM PAPAYA MOSAIC AGAINST SALMONELLA TYPHI AND OTHER ENTEROBACTERIAL PATHOGENS
EP2139993A2 (en) * 2007-04-27 2010-01-06 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
US20110104191A1 (en) * 2007-09-11 2011-05-05 Universite Laval Malva mosaic virus and virus-like particles and uses thereof
WO2010003219A1 (en) * 2008-06-17 2010-01-14 Universite Laval Compositions comprising salmonella porins and uses thereof as adjuvants and vaccines
WO2010012069A1 (en) * 2008-07-30 2010-02-04 Folio Biotech Inc. Multivalent vaccines based on papaya mosaic virus and uses thereof
US20130236491A1 (en) * 2010-12-09 2013-09-12 Iosif Grigorievich Atabekov Spherical nano and microparticles derived from plant viruses for the display of foreign proteins or epitopes
AU2012255595A1 (en) * 2011-05-13 2013-12-12 Folia Biotech Inc. Virus-like particles and process for preparing same
US9308251B2 (en) 2011-06-09 2016-04-12 Biomay Ag Peptide carrier fusion proteins as allergy vaccines
CA2908414A1 (en) * 2012-04-02 2013-10-10 Folia Biotech Inc. Recombinant papaya mosaic virus coat proteins and uses thereof in influenza vaccines
MX2016003653A (es) * 2013-09-19 2016-08-11 Folia Biotech Inc Virus de mosaico de papaya y particulas similares a virus en terapia de cancer.
US20180153984A1 (en) * 2015-04-30 2018-06-07 The Regents Of The University Of California Adjuvant particles comprising adenosine receptor antagonists
EP4277654A1 (en) 2021-01-18 2023-11-22 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
CN118684781A (zh) * 2023-03-21 2024-09-24 深圳赫兹生命科学技术有限公司 GnRH-VLP重组去势疫苗及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79880A0 (en) 1985-08-29 1986-11-30 Inst Medical W & E Hall Recombinant virus
US5977438A (en) * 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
EP0652967B1 (en) * 1990-08-15 1998-02-04 Therion Biologics Corporation Self-assembling replication defective hybrid virus particles
US5443969A (en) * 1992-10-29 1995-08-22 Rutgers University RNA packaging system
GB9414118D0 (en) * 1994-07-13 1994-08-31 Axis Genetics Ltd Modified plant viruses as vectors of heterologous peptides
CA2202761A1 (en) 1994-10-18 1996-04-25 Sean Nicholas Chapman Method of producing a chimeric protein
GB9607899D0 (en) 1996-04-17 1996-06-19 Scottish Crop Research Inst Virus-like particle
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
WO1998050071A1 (en) * 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
DE19752855C2 (de) * 1997-11-28 2003-04-03 Bundesrepublik Deutschland Let Retrovirale Pseudotyp-Vektoren mit modifizierten Oberflächen-Hüllproteinen und Verpackungszelle zu ihrer Herstellung für den selektiven Gentransfer
GB9806666D0 (en) 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
WO2000006717A2 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
FR2786773B1 (fr) 1998-12-03 2002-03-08 Univ Paris Curie Proteines d'enveloppe, methodes et utilisations
PL348766A1 (en) * 1998-12-04 2002-06-03 Biogen Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
DE19904800C1 (de) * 1999-02-05 2001-02-08 Eberhard Hildt Partikel zur Gentherapie
GB9921337D0 (en) * 1999-09-09 1999-11-10 Axis Genetics Plc Modified plant viruses
GB9924352D0 (en) 1999-10-14 1999-12-15 Hellendoorn Koen Methods,compositions and applications relating to the generation of novel plant viral particles
GB9924351D0 (en) * 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US6730306B1 (en) 2000-03-08 2004-05-04 Large Scale Biology Corporation Parvovirus vaccine as viral coat protein fusions
AUPQ661600A0 (en) 2000-03-31 2000-05-04 Macfarlane Burnet Centre For Medical Research Limited, The A nucleic acid construct and methods related thereto
IT1317046B1 (it) 2000-06-16 2003-05-26 Ist Superiore Sanita Proteina di fusione, particelle virali chimeriche che la espongono sulcapside, piante infettate con tali particelle, loro usi e composizioni
AU2001270164A1 (en) 2000-06-26 2002-01-08 The United States Of America As Represented By The Secretary Of Agriculture Production of vaccines using transgenic plants
DE60137230D1 (de) 2000-07-06 2009-02-12 Univ Georgetown Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen
GB0028319D0 (en) * 2000-11-20 2001-01-03 Univ Southampton Materials and methods relating to fusion proteins for inducing an immune response
ITRM20010332A1 (it) * 2001-06-11 2002-12-11 Ist Superiore Sanita Vaccini a subunita' e procedimenti per la loro produzione.
US8101189B2 (en) * 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
AU2003281246A1 (en) * 2002-07-05 2004-01-23 Denis Leclerc Adjuvant viral particle

Also Published As

Publication number Publication date
PT1523329E (pt) 2013-10-08
EP2272525A3 (en) 2011-11-16
ES2431963T3 (es) 2013-11-28
CA2434000C (en) 2012-07-17
CA2434000A1 (en) 2004-01-05
HK1075214A1 (en) 2005-12-09
US7641896B2 (en) 2010-01-05
WO2004004761A2 (en) 2004-01-15
EP1523329A2 (en) 2005-04-20
KR20050044886A (ko) 2005-05-13
DK1523329T3 (da) 2013-10-14
JP4953570B2 (ja) 2012-06-13
CN1665528A (zh) 2005-09-07
CN1665528B (zh) 2013-05-15
EP2272525A2 (en) 2011-01-12
WO2004004761A3 (en) 2004-05-06
US8282940B2 (en) 2012-10-09
US20050048082A1 (en) 2005-03-03
EP1523329B1 (en) 2013-07-24
MXPA05000287A (es) 2005-09-08
BR0312474A (pt) 2005-04-26
JP2006504644A (ja) 2006-02-09
US20090280145A1 (en) 2009-11-12
AU2003281246A1 (en) 2004-01-23

Similar Documents

Publication Publication Date Title
NO20050396L (no) Adjuvant viral partikkel
DK1450856T3 (da) Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
WO2008014521A3 (en) Improved vaccines and methods for using the same
WO2006086188A3 (en) Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
CY1110359T1 (el) Εμβολια με βαση σιρκοϊους χοιρων
RU2011128371A (ru) Модифицированные f протеины sv и способы их применения
WO2005118626A3 (en) Peptides for inducing a ctl and/or htl response to hepatitis c virus
IL164812A0 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
AR041880A1 (es) Composicion inmunogena
WO2011054011A3 (en) Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
WO2002072036A3 (en) Compositions and methods comprising west nile virus polypeptides
AU2002337083A1 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
ATE267256T1 (de) Hepatis e-virus antigene und dessen verwendungen
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
BR0112020A (pt) Partìculas tipo vìrus de bvdv
DK1334197T3 (da) Gær-afledt vaccine mod IPNV
SE9903534D0 (sv) Vaccin
DE69922212D1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano
DE60330795D1 (de) Impfstoff gegen west nile virus
ATE409705T1 (de) Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
ATE476197T1 (de) Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon
ATE413887T1 (de) Stress-protein-peptidkomplexe als impfstoffe gegen intrazelluläre pathogene

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application